Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis

Adult atopic dermatitis (AD), specifically late-onset phe- notypes, is characterized by a notable degree of clinical heterogeneity in terms of morphologic and topographic characteristics. Alongside the classic flexural AD presen- tation, adult patients can manifest other less common pheno- types, including prurigo nodularis-like, nummular eczema and generalized/erythrodermic, that may exhibit variations in immune and skin barrier proteins with potential influence on topical and systemic therapies' efficacy. Upadacitinib, a JAK 1 inhibitor indicated for treatment of patients aged ≥12years with moderate-to-severe AD, has shown good short- and long-term efficacy and a favourable safety profile both in randomized clinical trials and real-world studies. However, the effectiveness of upadacitinib in distinct AD clinical phenotypes has not been investigated.